Suppr超能文献

酪蛋白激酶II(CK2)和Ikaros对急性淋巴细胞白血病细胞增殖的调控

Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.

作者信息

Gowda Chandrika, Song Chunhua, Kapadia Malika, Payne Jonathon L, Hu Tommy, Ding Yali, Dovat Sinisa

机构信息

Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA.

Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA; Loma Linda University, Loma Linda, CA, USA.

出版信息

Adv Biol Regul. 2017 Jan;63:71-80. doi: 10.1016/j.jbior.2016.09.003. Epub 2016 Sep 18.

Abstract

The IKZF1 gene encodes the Ikaros protein, a zinc finger transcriptional factor that acts as a master regulator of hematopoiesis and a tumor suppressor in leukemia. Impaired activity of Ikaros is associated with the development of high-risk acute lymphoblastic leukemia (ALL) with a poor prognosis. The molecular mechanisms that regulate Ikaros' function as a tumor suppressor and regulator of cellular proliferation are not well understood. We demonstrated that Ikaros is a substrate for Casein Kinase II (CK2), an oncogenic kinase that is overexpressed in ALL. Phosphorylation of Ikaros by CK2 impairs Ikaros' DNA-binding ability, as well as Ikaros' ability to regulate gene expression and function as a tumor suppressor in leukemia. Targeting CK2 with specific inhibitors restores Ikaros' function as a transcriptional regulator and tumor suppressor resulting in a therapeutic, anti-leukemia effect in a preclinical model of ALL. Here, we review the genes and pathways that are regulated by Ikaros and the molecular mechanisms through which Ikaros and CK2 regulate cellular proliferation in leukemia.

摘要

IKZF1基因编码Ikaros蛋白,这是一种锌指转录因子,在造血过程中起主要调节作用,在白血病中作为肿瘤抑制因子。Ikaros活性受损与预后不良的高危急性淋巴细胞白血病(ALL)的发生有关。调节Ikaros作为肿瘤抑制因子和细胞增殖调节因子功能的分子机制尚未完全清楚。我们证明Ikaros是酪蛋白激酶II(CK2)的底物,CK2是一种在ALL中过表达的致癌激酶。CK2对Ikaros的磷酸化会损害Ikaros的DNA结合能力,以及Ikaros在白血病中调节基因表达和作为肿瘤抑制因子的能力。用特异性抑制剂靶向CK2可恢复Ikaros作为转录调节因子和肿瘤抑制因子的功能,从而在ALL的临床前模型中产生治疗性抗白血病作用。在此,我们综述了受Ikaros调节的基因和信号通路,以及Ikaros和CK2在白血病中调节细胞增殖的分子机制。

相似文献

1
Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.
Adv Biol Regul. 2017 Jan;63:71-80. doi: 10.1016/j.jbior.2016.09.003. Epub 2016 Sep 18.
4
5
Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
Blood. 2015 Oct 8;126(15):1813-22. doi: 10.1182/blood-2015-06-651505. Epub 2015 Jul 28.
7
Protein signaling and regulation of gene transcription in leukemia: role of the Casein Kinase II-Ikaros axis.
J Investig Med. 2016 Mar;64(3):735-9. doi: 10.1136/jim-2016-000075. Epub 2016 Feb 9.
8
Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.
Adv Biol Regul. 2017 Aug;65:16-25. doi: 10.1016/j.jbior.2017.06.001. Epub 2017 Jun 13.
9
Regulation of Small GTPase Rab20 by Ikaros in B-Cell Acute Lymphoblastic Leukemia.
Int J Mol Sci. 2020 Mar 3;21(5):1718. doi: 10.3390/ijms21051718.
10
Ikaros, CK2 kinase, and the road to leukemia.
Mol Cell Biochem. 2011 Oct;356(1-2):201-7. doi: 10.1007/s11010-011-0964-5. Epub 2011 Jul 13.

引用本文的文献

2
Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL.
Blood. 2025 Mar 27;145(13):1407-1421. doi: 10.1182/blood.2024024130.
3
Yeast Protein Asf1 Possesses Modulating Activity towards Protein Kinase CK2.
Int J Mol Sci. 2022 Dec 12;23(24):15764. doi: 10.3390/ijms232415764.
4
Emerging role of Protein Kinase CK2 in Tumor immunity.
Front Oncol. 2022 Dec 1;12:1065027. doi: 10.3389/fonc.2022.1065027. eCollection 2022.
5
6
Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms.
Pharmaceutics. 2022 Jan 30;14(2):331. doi: 10.3390/pharmaceutics14020331.
7
Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
Leukemia. 2021 May;35(5):1267-1278. doi: 10.1038/s41375-021-01132-5. Epub 2021 Feb 2.
10
Sparse multiple co-Inertia analysis with application to integrative analysis of multi -Omics data.
BMC Bioinformatics. 2020 Apr 15;21(1):141. doi: 10.1186/s12859-020-3455-4.

本文引用的文献

3
Protein signaling and regulation of gene transcription in leukemia: role of the Casein Kinase II-Ikaros axis.
J Investig Med. 2016 Mar;64(3):735-9. doi: 10.1136/jim-2016-000075. Epub 2016 Feb 9.
5
Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia.
Leukemia. 2016 Jun;30(6):1436-40. doi: 10.1038/leu.2015.331. Epub 2015 Dec 7.
6
Application of genome editing technologies to the study and treatment of hematological disease.
Adv Biol Regul. 2016 Jan;60:122-134. doi: 10.1016/j.jbior.2015.09.005. Epub 2015 Sep 26.
7
Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
Blood. 2015 Oct 8;126(15):1813-22. doi: 10.1182/blood-2015-06-651505. Epub 2015 Jul 28.
8
Foreword: "The PI3-kinase/Akt pathway: From signaling to diseases".
Adv Biol Regul. 2015 Sep;59:1-3. doi: 10.1016/j.jbior.2015.07.001. Epub 2015 Jul 18.
9
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.
Mol Cell Ther. 2015 Mar 20;3:2. doi: 10.1186/s40591-015-0040-8. eCollection 2015.
10
The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
Front Pharmacol. 2015 Mar 31;6:70. doi: 10.3389/fphar.2015.00070. eCollection 2015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验